on the planning and reporting of the assessment of risk evaluation and mitigation strategies (REMS) for drugs and biologics. The development of a REMS Assessment Plan including the impact on the selection of metrics and data sources is discussed. Also discussed in the guidance are considerations for assessing REMS impact on patient access to drugs and recommendations on reporting REMS findings to FDA.

	Specifically, the guidance covers assessment categories, selecting metrics and sources of assessment data, and thresholds for REMS effectiveness. The guidance does not discuss the design or development of REMS.

Industry News

PharmTech News

Quality Assurance/Quality Control

Quality Systems

Regulatory Filings and Submissions

Regulatory/GMP Compliance

The guidance describes how to develop a REMS Assessment Plan, discusses the impact of REMS on patient access to drugs, and gives recommendations on reporting REMS findings to FDA.